Submit Feedback
Recent searches
    Trending searches
    +

    Bristol-Myers Squibb Company Overview

    Company: Bristol-Myers Squibb Company
    CEO: Dr. Christopher S. Boerner Ph.D.
    Symbol: BMY
    Exchange: NYSE
    Industry: Drug Manufacturers - General
    Sector: Healthcare
    About

    Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's productslude Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

    Continue reading...
    • Address:

      430 East 29th Street

    • City | State | Zip | Country:

      New York | NY | 10016 | US

    • Phone:

      212 546 4000

    • Website:

      https://www.bms.com

    Bristol-Myers Squibb Company (BMY)

    • Stock Price
    • Volume
    56.81 -8.42 -12.91%
    Past 5 Years
    • 1D
    • 1W
    • 1M
    • 3M
    • 6M
    • YTD
    • 1Y
    • 2Y
    • 5Y
    • 10Y
    • ALL

    Revenue

    Bristol-Myers Squibb Company annual revenue was $45.01B in 2023.

    Net Income

    Bristol-Myers Squibb Company annual net income was $8.03B in 2023.

    Employees

    Bristol-Myers Squibb Company annual employee count was 34,100 in 2023.

    Revenue by Segment

    No Data Available !!

    Revenue by Region

    No Data Available !!

    Income Statement

    Operating Income

    Bristol-Myers Squibb Company annual operating income was $17.24B in 2023.

    Research & Development

    Bristol-Myers Squibb Company annual research & development expense was $9.30B in 2023.

    Tax Rate (%)

    Bristol-Myers Squibb Company annual Tax Rate was 5.00% in 2023.

    Assets & Liabilities | Cash Flow

    Total Assets

    Bristol-Myers Squibb Company annual total assets was $95.16B in 2023.

    Total Liabilities

    Bristol-Myers Squibb Company annual total liabilities was $65.67B in 2023.

    Capital Expenditure

    Bristol-Myers Squibb Company annual capital expenditures was -$1.21B in 2023.

    Ratios

    Return on Equity (ROE)

    Bristol-Myers Squibb Company annual return on equity(ROE) was 27.27% in 2023.

    Return on Assets (ROA)

    Bristol-Myers Squibb Company annual return on assets(ROA) was 8.43% in 2023.

    Debt to Equity

    Bristol-Myers Squibb Company annual debt to equity was 135.14% in 2023.

    Profitability

    Gross Profit Margin (%)

    Bristol-Myers Squibb Company annual gross profit margin was 76.24% in 2023.

    Operating Income Margin (%)

    Bristol-Myers Squibb Company annual operating income margin was 38.31% in 2023.

    Net Income Margin (%)

    Bristol-Myers Squibb Company annual net income margin was 17.83% in 2023.

    Earning Per Share

    Bristol-Myers Squibb Company annual earning per share was $3.88 in 2023.

    EBITDA

    Bristol-Myers Squibb Company annual EBITDA was $19.42B in 2023.

    Free Cash Flow (FCF)

    Bristol-Myers Squibb Company annual free cash flow(FCF) was $12.65B in 2023.

    Valuation

    Enterprise value

    Bristol-Myers Squibb Company annual enterprise value was $136.16B in 2023.

    Enterprise value to Revenue

    Bristol-Myers Squibb Company annual enterprise value to revenue was 3.03 in 2023.

    Enterprise value to EBITDA

    Bristol-Myers Squibb Company annual enterprise value to EBITDA was 7.01 in 2023.

    Competitors’ Revenue

    Related company

    Submit feedback to Bullfincher